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Abstract
Introduction: Innate defence regulator (IDR) peptides are synthetic cationic peptides, variants of naturally
occurring innate immune effector molecules known as host defence peptides. IDR peptides were recently
demonstrated to limit infection-associated inflammation selectively without compromising host innate immune
functions. This study examined the impact of a 12-amino acid IDR peptide, IDR-1002, in pro-inflammatory cytokine
interleukin (IL)-1b-induced responses in synovial fibroblasts, a critical cell type in the pathogenesis of inflammatory
arthritis.
Methods: Human fibroblast-like synoviocytes (FLS) were stimulated with IL-1b in the presence and absence of IDR-
1002. Production of enzyme matrix metalloproteinase-3 (MMP-3) and IL-1-receptor antagonist (IL-1RA) was
monitored by enzyme-linked immunosorbent assay (ELISA), and various chemokines were evaluated by using
multiplex cytometric bead array. Transcriptional responses were analyzed by quantitative real-time PCR. The impact
on IL-1b-induced proteome was investigated by quantitative proteomics by using isobaric tags. IL-1b-induced
pathways altered by IDR-1002 implicated by the proteomics analyses were further investigated by using various
immunochemical assays. Cellular uptake of the peptide was monitored by using a biotinylated IDR-1002 peptide
followed by microscopy probing with streptavidin-Alexa Fluor.
Results: This study demonstrated that IDR-1002 suppressed the production of IL-1b-induced MMP-3 and monocyte
chemotactic protein-1 (MCP-1); in contrast, IDR-1002 enhanced the production of IL-1RA, without neutralizing all
chemokine responses. IDR-1002 altered the IL-1b-induced proteome primarily by altering the expression of
members of nuclear factor kappa-B (NF-B) and c-Jun N-terminal kinase (JNK) pathways. The proteomics data also
suggested that IDR-1002 was altering the transcription factor HNF-4a-mediated responses, known to be critical in
metabolic regulation. With various immunochemical assays, it was further demonstrated that IL-1b-induced NF-B,
JNK, and p38 mitogen-activated protein kinase (MAPK) activations were significantly suppressed by IDR-1002.
Conclusions: This study demonstrates the ability of an innate immune-modulatory IDR-peptide to influence the IL-
1b-induced regulatory pathways and selectively to suppress inflammatory responses in synovial fibroblasts. The
results of this study provide a rationale for examining the use of IDR-peptides as potential therapeutic candidates
for chronic inflammatory diseases such as inflammatory arthritis.
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Cationic host defense peptides (HDPs) are naturally
occurring effector molecules of innate immunity. These
peptides are 12 to 50 amino acids in length, with a net
positive charge ranging from +2 to +7 with up to 50%
hydrophobic amino acids [1]. HDPs exhibit a wide vari-
ety of immunomodulatory functions and delicately mod-
ulate inflammatory responses without compromising the
elements of immunity required for resolution of infec-
tions [2-8]. HDPs exhibit anti-inflammatory effects by
suppressing certain pro-inflammatory pathways, upregu-
lating anti-inflammatory mechanisms (for example, IL-
10), and intervening in the activation of nuclear factor
(NF)-B via multiple mechanisms [3]. A broad spectrum
of cationic HDPs are expressed in human synovium tis-
sues with differential expression patterns under inflam-
matory conditions [9]. However, the role of HDPs in
synovium biology is not well characterized. It has been
suggested that induction of HDPs by vitamin D may
play a role in the protection against autoimmune dis-
eases such as rheumatoid arthritis (RA) [10]. Therefore,
HDPs and their derivatives are attractive candidates for
modulating the inflammatory responses in chronic
inflammatory disorders, including in inflammatory
arthritis.
HDPs are widely diverse in sequence and structure,
and this wide repertoire provides an extensive template
for designing short synthetic peptides with optimized
activities and reduced cytotoxicities [11-13]. The syn-
thetic variants of HDP are known as innate defence reg-
ulator (IDR) peptides [14]. Two IDR peptides, IDR-1
and IDR-1002, have been shown to protect against
infections largely by modulating innate immune
responses of the host and upregulating anti-inflamma-
tory mechanisms [15,16]. To our knowledge, no studies
to date have investigated the potential of IDR peptides
in limiting inflammation in immune-mediated chronic
inflammatory disorders such as inflammatory arthritis.
The complex pathophysiology of arthritis involves
synergistic interplay primarily between mesenchymal
cells such as fibroblast-like synoviocytes (FLS) and
immune cells (for example, macrophages and T-lympho-
cytes). Activation of FLS by pro-inflammatory cytokines
results in the production of inflammatory cytokines,
chemokines, and matrix-degrading matrix metallopepti-
dases (MMPs), which lead to the destruction of articular
cartilage and bone [17]. TNF-a and IL-1b are two
inflammatory cytokines that are well defined as critical
inflammatory mediators in arthritis [18]. TNF-a is pro-
posed to be the dominant pro-inflammatory cytokine in
the inflammatory manifestations of synovitis, whereas
IL-1b is thought to be important in the destructive
potential of chronic joint inflammation [19,20]. IL-1b
induces the production of MMP-3 in cell types such as
FLS, chondrocytes, and macrophages in arthritic joints,
and the subsequent elevated level of MMP-3 mediates
cartilage and bone destruction, directly contributing to
the pathogenesis of the disease [21]. Efficacious thera-
peutic strategies have been developed to target each of
these cytokines. Despite this, a major consideration
regarding therapeutic agents targeting inflammatory
cytokines such as TNF-a is the increased associated risk
of infections and neoplasm [22,23]. This highlights the
need for the development of alternate strategies for the
management of chronic inflammatory arthropathies. We
hypothesized that one such strategy would be to exam-
ine the use of selectively immune-modulatory agents
such as IDR peptides [24].
In this study, we demonstrated that a 12-amino-acid
IDR peptide, IDR-1002 [16], suppressed IL-1b-mediated
cellular responses in human FLS, especially MMP-3 and
MCP-1 production. However, IDR-1002 did not neutra-
lize all IL-1b-induced chemokine responses that are
required for resolution of infections. In contrast, this
peptide enhanced the production of negative regulators
of IL-1b (for example, IL-1-receptor antagonist (IL-
1RA). These observations were consistent with the para-
digm of the selective anti-inflammatory mechanism of
host defense and IDR peptides [3,15,16]. We explored
the molecular mechanism of regulation of IL-1b-induced
responses by IDR-1002 in FLSs, by using quantitative
proteomics and other immunochemical assays. We
demonstrated that IDR-1002 suppressed IL-1b-induced
NF-B, c-Jun kinase (JNK), and p38 mitogen-activated
protein kinase (MAPK) activation in synovial fibroblasts.
This study provides a rationale for further examining
the use of IDR peptides as potential therapeutics for the
management of inflammatory arthritis and possibly
other diseases characterized by chronic inflammation.
Materials and methods
Cell isolation and culture
Synovial tissues were obtained from patients with
osteoarthritis (OA) or rheumatoid arthritis (RA) with
informed consent in accordance with a protocol
approved by the Institutional Review Board at the Uni-
versity of Manitoba. Human FLS were isolated from the
synovial tissues, as previously described [25]. In brief,
the tissues were digested with 1 mg/ml collagenase and
0.05 mg/ml hyaluronidase (Sigma Aldrich) in Hanks’
balanced salt solution (Gibco; Invitrogen Inc., Burling-
ton, ON, Canada) for 1 to 2 hours at 37°C. Cells were
washed and cultured in DMEM media (Gibco), supple-
mented with sodium pyruvate and nonessential amino
acids (referred to as complete DMEM media henceforth)
containing 10% (vol/vol) fetal bovine serum (FBS) in a
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human FLS (ex vivo) were seeded at 2 × 10
4 cells/ml,
either 0.5 ml per well in 48-well tissue-culture plate, or
3 ml per well in six-well tissue-culture plate, as required,
and cultured in complete DMEM media containing 10%
(vol/vol) FBS overnight. The following day, the culture
media was changed to complete DMEM containing 1%
(vol/vol) FBS before the addition of the various stimu-
lants. A rabbit synoviocyte cell line HIG-82 (ATCC
CRL-1832) was cultured in Ham’s F-12 growth medium
containing glutamine (Gibco) supplemented with
sodium pyruvate (referred to as complete F-12 media
henceforth), containing 10% (vol/vol) FBS in a humidi-
fied incubator at 37°C and 5% CO2. Confluent human
FLS or HIG-82 cells were trypsinized with 1:3 dilution
of 0.5% trypsin-EDTA (Invitrogen) in Hanks’ balanced
salt solution. Cellular cytotoxicity was evaluated by
monitoring the release of lactate dehydrogenase (LDH)
by using a colorimetric detection kit (Roche Diagnostics,
Laval, QC, Canada).
Peptides and recombinant cytokines
Recombinant human cytokines TNF-a and IL-1b were
obtained from eBioscience, Inc (San Diego, CA, USA).
IDR-1002 peptide (VQRWLIVWRIRK-NH2) [16] was
synthesized by using F-moc chemistry at the Nucleic
Acid/Protein Synthesis Unit of University of British
Columbia, Vancouver, BC, Canada, and IDR-1 peptide
(KSRIVPAIPVSLL-NH2) [15] was obtained from Gen-
Script USA Inc. (Piscataway, NJ, USA). The peptides
were resuspended in endotoxin-free water, aliquoted,
and stored at -20°C. Based on previous studies demon-
strating the anti-inflammatory and anti-infective proper-
ties of the IDR peptides, in in vitro cell studies and in
vivo models of various infections models [15,16], and on
preliminary dose-titration studies, standard doses were
used for IDR-1002 (100 μg/ml) and IDR-1 (200 μg/ml)
for all experiments.
ELISA and multiplex flow cytometry
Tissue culture (TC) supernatants were centrifuged at
1,500 g for 7 minutes to obtain cell-free samples, ali-
quoted, and stored at -20°C until further use. Produc-
tion of MMP-3 was monitored by using Quantikine
human MMP-3 (total) ELISA kit (R&D Systems, Inc.
Minneapolis, MN, USA), as per the manufacturer’s
instructions. Production of IL-1RA was monitored in
the TC supernatants by using specific antibody pairs
from eBioscience, Inc. The production of chemokines
IL-8, RANTES, MIG, MCP-1, IP-10 was determined by
using a preconfigured multiplex BDCytometric Bead
A r r a y( C B A )h u m a nc h e m o k i n ek i tb yu s i n gt h eF A C S
Calibur flow cytometer (BD Biosciences, Mississauga,
ON, Canada) as per the manufacturer’s instructions.
The concentration of the cytokines or chemokines in
the TC supernatants was evaluated by establishing a
standard curve with serial dilutions of the recombinant
human cytokines or chemokines, as required.
Quantitative real-time (qRT-PCR)
Human FLS were stimulated with either IL-1b (10 ng/
ml), IDR-1002, or the combination of IL-1b and IDR-
1002, for 2 hours. RNA was isolated by using the Qia-
gen RNeasy kit as per the manufacturer’si n s t r u c t i o n s .
Gene expression was subsequently analyzed with qRT-
PCR by using SuperScript III Platinum Two-Step qRT-
PCR Kit with SYBR Green (Invitrogen), according to the
manufacturer’s instructions, in the ABI PRISM 7300
sequence-detection system (Applied Biosystems). Fold
changes were calculated by the comparative Ct method
[26], after normalization with 18sRNA. The list of pri-
mers used is shown in Table 1.
Quantitative proteomics using isobaric tag for relative
and absolute quantitation (iTRAQ)
Amine-modifying iTRAQ reagents multiplex kit
(Applied Biosystems) was used for relative quantitation
of proteins in human FLS stimulated with IL-1b in the
presence and absence of IDR-1002 compared with unsti-
mulated (control) cells. Human FLS (2 × 10
4/ml) were
seeded in a total volume of 3 ml per well in a six-well
tissue-culture plate in complete DMEM media contain-
ing 10% FCS. The cells were allowed to adhere over-
night. The following day, the media was changed to 3
ml complete DMEM containing 1% FCS per well. The
cells were either unstimulated or treated with IL-1b (10
ng/ml) in the presence or absence of IDR-1002. The
peptide was added 45 min before stimulation with IL-
1b. After 24 hours of stimulation, the cells were washed
with cold PBS and lysed in 250 μl of buffer containing
10 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA,
1% NP-40, and protease inhibitor cocktail (Sigma-
Aldrich), on ice for 30 minutes with intermittent vortex-
ing. Cells were centrifuged at 10,000 g for 10 minutes at
4°C. Total protein content was estimated in each cell
lysate by using micro BCA assay (Pierce; Thermo Scien-
tific, Rockford, IL, USA) with a bovine serum albumin
(Sigma-Aldrich) standard curve. The samples were acet-
one precipitated at -20°C overnight. Proteins were dis-
solved in 20 μl of iTRAQ dissolution buffer (Applied
Table 1 Summary of primers used for quantitative real-
time PCR
Gene Forward primer Reverse Primer
IL-1RA ttggaaggctctgaacctca ctgaaggcttgcatcttgct
SIGIRR ctcagagccatgccaggt cctcagcacctggtcttca
18sRNA gtaacccgttgaaccccatt ccatccaatcggtagtagcg
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turer’s instructions. In brief, proteins were reduced and
the cysteines blocked by using the reagents in the kit,
followed by digestion of the protein samples with pro-
vided trypsin solution overnight at 37°C. The trypsin-
digested protein samples were labelled with the iTRAQ
isobaric tags as follows: unstimulated (control) sample
was labeled with iTRAQ isobaric tag 115; IL-1b-stimu-
lated sample, with tag 116; and the isobaric tag 117 was
used for labeling the sample obtained from cells treated
with IL-1b in the presence of IDR-1002. The contents
from each of the iTRAQ reagent-labeled sample was
combined together in 1:1 ratio and processed for nano-
flow liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) by using a QStar Elite mass
spectrometer (ABSciex, Toronto, ON, Canada).
Monitoring activation of NF-B
Rabbit synoviocyte HIG-82 cells were transiently trans-
fected with pNFB-MetLuc2-Reporter Vector (Clontech
Laboratories Inc., Mountain View, CA, USA) or the pro-
vided control vector as per the manufacturer’si n s t r u c -
tions. Various stimulants were added to the transfected
cells in culture media containing 1% (vol/vol) FBS. The
cells were stimulated with recombinant human IL-1b in
t h ep r e s e n c ea n da b s e n c eo fI D R - p e p t i d e s ,e i t h e rI D R -
1002 or IDR-1, for 6 hours. The peptides were added at
the time of cytokine stimulation. The activation of NF-
B was monitored by using the Ready-To-Glow
Secreted NF-B Luciferase Reporter Assay (Clontech) as
per the manufacturer’s instructions.
Human OA FLS were stimulated with IL-1b in the
presence and absence of IDR-peptides, IDR-1002 and
IDR-1. The peptides were added either 45 minutes
before, or at the time of cytokine stimulation. Nuclear
extracts were prepared by using NE-PER extraction
reagents (Thermo Fisher Scientific) as per the manufac-
turer’s instructions. Nuclear extracts (5 μg) were
resolved on 4% to 12% NuPAGE Bis-Tris gels (Invitro-
gen) and probed with antibodies specific for either NF-
B subunit p50 (Cell Signaling Technology) or antibody
to b-actin (Thermo Fisher Scientific) by using
immunoblots.
Monitoring functional JNK activity
Human FLS (5 × 10
4/ml) were seeded in a total volume
of 20 ml per 75-cm
2 tissue-culture flask in complete
DMEM media containing 10% (vol/vol) FBS for each
condition. The cells were allowed to adhere overnight.
The next day, the media was changed to 10 ml complete
DMEM containing 1% (vol/vol) FBS. The cells were
either unstimulated or treated with IL-1b (10 ng/ml) in
the presence or absence of IDR-1002 for 15 minutes.
IL-1b is known to induce JNK activation after 15
minutes in human FLSs [27]. Total protein concentra-
tion was evaluated for each cell lysate by using micro
BCA (Thermo Scientific). Kinase activity specific to JNK
was monitored by using the JNK activity assay kit
(Abcam Inc.) as per the manufacturer’s instructions. In
brief, 20 μg of total protein per cell lysate was used for
immunoprecipitation (IP) by using a JNK-specific anti-
body. The eluate was treated with c-Jun substrate and
ATP mixture. Subsequent phosphorylation of the c-Jun
substrate was evaluated by probing immunoblots with
anti-phospho-c-Jun (Ser73)-specific antibody.
Monitoring p38 MAPK activity
Human FLS (5 × 10
4/ml) were seeded in a total volume
of 20 ml per 75-cm
2 tissue culture flask in complete
DMEM media containing 10% (vol/vol) FBSs for each
condition, allowed to adhere overnight, followed by
changing the media to 1% (vol/vol) FBS. The cells were
either unstimulated or treated with IL-1b (10 ng/ml) in
the presence or absence of either IDR-1002 or IDR-1
for 15 minutes. The peptides were added either (a) 45
minutes before cytokine stimulation, or (b) simultaneous
with cytokine stimulation. The p38 MAPK activation
has been demonstrated in human FLSs on stimulation
with IL-1b for 15 minutes [28]. Total protein concentra-
tion was evaluated for each cell lysate by using micro
BCA (Thermo Scientific). Kinase activity specific to p38
MAPK was monitored by using the p38 MAPK activity
assay kit (Cell Signaling Technology) as per the manu-
facturer’s instructions. In brief, 10 μg of total protein
per cell extract was used for IP by using a p38 MAPK-
specific monoclonal antibody. Kinase activity was evalu-
ated by treating the IP eluates in the presence of ATP
and kinase substrate ATF-2 fusion protein. Phosphoryla-
tion of the substrate ATF-2 was monitored with Wes-
tern blot by using a phospho-ATF-2 (Thr76) antibody.
Immunoblots
The IP eluates or nuclear extracts were electrophoreti-
cally resolved on a 4% to 12% NuPAGE Bis-Tris gels
(Invitrogen Corporation), followed by transfer to nitro-
cellulose membranes (Millipore). The nitrocellulose
membranes were blocked with TBST (20 mM Tris pH
7.5, 150 mM NaCl, 0.1% Tween 20) containing 5% (vol/
vol) skimmed milk powder. Affinity-purified HRP-linked
anti-rabbit secondary antibody was used for detection.
The membranes were developed with Amersham ECL
detection system (GE Healthcare, Baie d’Urfe, QC,
Canada) according to the manufacturer’s instructions.
Microscopy
A modified IDR-1002 was synthesized by incorporating
a C-terminal cysteine (IDR-1002C) to allow the presence
of a thiol group for biotinylation of the peptide. IDR-
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brief, IDR-1002C was biotinylated by using desthiobiotin
polyethyleneoxide iodoacetamide (Sigma) as per the
manufacturer’s instructions. Biotinylated IDR-1002 pep-
tide (IDR-1002B) was purified by HPLC and confirmed
by using MALDI mass spectrometry. To facilitate moni-
toring cellular uptake of the peptide, 150 μl of human
FLS (2 × 10
4/ml) was seeded in 96-well glass-bottom
Nunc plates in DMEM containing 10% (vol/vol) FBS,
overnight. The following day, the media was changed to
DMEM containing 1% (vol/vol) FBS. The cells were sti-
mulated with IDR-1002B (100 μg/ml) for 0, 15, or 30
min. The cells were fixed by using 2% (vol/vol) para-for-
maldehyde, the reaction quenched with 10 mM ethano-
lamine and permeabilized with 0.1% Triton × 100. The
cells were washed in PBS and blocked with 3% (vol/vol)
F B Si nP B S .T h ec e l l sw e r es t a i n e df o ra c t i nb yu s i n g
Alexa Fluor 546 phalloidin (Invitrogen) and stained with
Streptavidin Alexa Fluor 488 conjugate (Invitrogen) to
detect biotin. The cells were counterstained with
Hoescht 33258 (Invitrogen) for nuclear staining.
Results
IDR-1002 suppressed IL-1b-induced MMP-3, but induced
negative regulators of IL-1b in human FLS
IL-1b induces the production of MMP-3 in FLS, which
contributes to the destruction of cartilage and bone in
arthritic joints [21]. We therefore evaluated the impact
of IDR peptides on IL-1b-induced MMP-3 production.
Human FLS isolated from OA and RA synovial tissues
were stimulated with IL-1b (10 ng/ml) in the presence
and absence of IDR peptides. The peptides were added
a tt h et i m eo fc y t o k i n es t i m u lation. The peptides were
not cytotoxic to the FLS under any experimental condi-
tion, as determined by monitoring the TC supernatants
for the release of LDH after 24 hours of stimulation
(data not shown). TC supernatants were monitored after
24 hours of stimulation for MMP-3 production by
ELISA. IL-1b-induced MMP-3 production was quantita-
tively similar in OA and RA FLS (Figure 1). IL-1b-
induced MMP-3 was significantly suppressed by 70% ±
8% (P < 0.05) in the presence of IDR-1002 in OA FLS
(Figure 1a). IL-1b-induced MMP-3 was also significantly
suppressed by 61% ± 14% (P <0 . 0 5 )i nt h ep r e s e n c eo f
IDR-1002 in RA FLS (Figure 1b). In contrast, IDR-1 [15]
did not significantly suppress IL-1b-induced MMP-3
production in either OA or RA FLS (Figure 1). Previous
studies have shown that human primary OA FLS after
stimulation with a pro-inflammatory cytokine such as
IL-1b, upregulates the expression of MMP-3, MMP-13,
MMP-1, various chemokines, activates transcription fac-
tor NF-B, induces the phosphorylation of ERK, p38,
and JNK MAPK, and phosphorylation of AKT, all criti-
cal in the induction of inflammatory responses [30,31].
Therefore, we proceeded to investigate further the cellu-
lar responses and molecular mechanism of IDR-1002 by
using human OA FLS stimulated with pro-inflammatory
cytokines. Our approach was consistent with other stu-
dies that have used similar ex vivo methods with FLSs
from OA tissues to investigate potential therapeutic tar-
gets and molecular mechanisms of candidate therapeu-
tics for anti-inflammatory interventions [31,32].
Further to investigate cellular responses in the pre-
sence of IDR-1002, human OA FLS were stimulated
with pro-inflammatory cytokines, and the TC superna-
tant was monitored for MMP-3 production after 24
hours and IL-1RA production after 48 hours. MMP-3
production was increased by threefold on stimulation of
FLS with cytomix, a combination of 10 ng/ml each of
IL-1b and TNF-a (Figure 2a), compared with IL-1b
alone (Figure 1a). This elevated level of cytomix-induced
MMP-3 was also suppressed by 56% ± 10% (P < 0.05)
by the peptide IDR-1002 (Figure 2a). IDR-1002 by itself
did not induce MMP-3 production above the back-
ground amount observed in unstimulated control FLS
(Figures 1 and 2a). In contrast, IDR-1002 synergistically
enhanced the production of IL-1b-induced IL-1RA by
threefold, which was not seen with IDR-1 peptide (Fig-
ure 2b). Consistent with this, on monitoring gene
expression of endogenous inhibitors of IL-1b [33], it was
demonstrated that IDR-1002 by itself induced the gene
expression of IL-1RA by > 10-fold, and did not suppress
the IL-1b-induced gene expression of IL-1RA (Figure
2c). Similarly, gene expression of another negative regu-
lator of IL-1b, SIGIRR (single Ig IL-1R related molecule,
also known as TIR8) was induced more than ninefold (P
< 0.05) by the peptide IDR-1002 relative to that
observed in cells stimulated with IL-1b (Figure 2d).
Taken together, these results indicated that IDR-1002
suppressed IL-1b-induced pro-inflammatory MMP-3
production and in contrast enhanced the expression of
negative regulators of IL-1b, in human FLS.
IDR-1002 altered the IL-1b-induced proteome in human
FLS
As an approach to globally defining the impact of IDR-
1002 on IL-1b-induced protein production, we under-
took a quantitative proteomic analysis. Human OA FLS
were pretreated with IDR-1002 45 min before IL-1b (10
ng/ml) stimulation for 24 hours. The TC supernatants
were monitored for MMP-3 and chemokine production.
IDR-1002 significantly (P < 0.01) suppressed IL-1b-
induced MMP-3 production by 80% (Figure 3a) and
suppressed chemokine MCP-1 production by > 60%
(Figure 3b) after 24 hours. However, IL-1b-induced neu-
trophil chemokine IL-8 production (Figure 3c) was only
modestly suppressed (by 20%, P < 0.05) by the peptide.
These observations were consistent with previous
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inflammation without abrogating certain chemokine
responses that are required for cell movement and
recruitment essential to combat infectious assault [3].
The FLS lysates were labeled with iTRAQ reagents;
isobaric tag 115 for unstimulated (control) samples, tag
116 for IL-1b-stimulated cells, and the tag 117 for cells
treated with the combination of IL-1b and IDR-1002.
Samples from three independent donors were individu-
ally examined by LC-MS/MS. The mass spectrometry
data were analyzed by using ProteinPilot (Applied Bio-
systems). Only those proteins that were identified in at
least two of the three independent experiments with
95% confidence were selected for further analysis. In
total, 517 proteins were identified from at least two of
the three independent samples stimulated with IL-1b.
Proteins were defined to be induced if the relative ratios
compared with the unstimulated controls (fold change)
were at least mean ± 1.3 standard deviations (which
meant that 20% of the population was differentially
expressed). Forty-eight of the 517 proteins were defined
to be induced on stimulation with IL-1b.O ft h e s e4 8
IL-1b-induced proteins, 11 proteins were found to be
suppressed by IDR-1002 between 20% and 60% (Addi-
tional file 1, Table s1). To define immunity-related path-
ways that may be involved in the alteration of IL-1b-
induced responses in the presence of IDR-1002, we
undertook a network-based approach. The eleven IL-1b-
induced protein candidates that were suppressed by
IDR-1002 (Additional file 1, Table S1) were submitted
to InnateDB biomolecular interaction database, which
facilitates systems-level analysis of mammalian immune
genes and protein products [34].
The computational network analysis demonstrated
that several members of NF-B and the mitogen-acti-
vated protein kinase-8 (MAPK8) pathways were direct
interactors of the selected protein candidates (Additional
file 1, Table S2). Four of the 11 selected proteins partici-
pated in interactions with candidates known to partici-
pate in NF-B activation, including (i) IBE; which
activates NF-B via TRAF-2 [35], (ii) TRAF-6; an NF-
B regulator that plays a critical role in human autoim-
mune diseases including arthritis [36], (iii) TNF-receptor
superfamily member TNFRSF21; which activates NF-B
and MAPK8 pathways [37,38], and (iv) mitogen-acti-
vated protein kinase kinase kinase-14 (MAP3K14), also
called the NF-kappa-beta-inducing kinase (NIK); which
activates NF-B via TRAF-2 [39]. Several members of
the c-Jun N-terminal kinases of the JNK pathway [40],
MAPK8, MAPK8IP1, and TNFRSF21, were also identi-
fied in the interaction protein network of IL-1b-induced
candidates that were suppressed by IDR-1002 in human
FLS cells (Additional file 1, Table S2). Another interest-
ing observation from this computational analysis was
that genes encoding for four of the 11 selected protein
candidates had binding sites for the transcription factor
hepatocyte nuclear factor (HNF)-4a (Additional file 1,
Table S2).
IDR-1002 inhibited IL-1b-induced activation of JNK and
p38 MAPK
The network-based interrogation of the proteomics data
indicated that members of the JNK pathways (for exam-
ple, MAPK8, MAPK8IP1) were modulated by the pep-
tide IDR-1002. Therefore, we evaluated the impact of
IDR-1002 on IL-1b-induced activation of JNK in human
M
M
P
-
3
 
(
n
g
/
m
l
)


0
5
10
15
20
25 

NS
0
5
10
15
20
25
30
NS


Ctrl                              IL-1ECtrl                                   IL-1E
A.                                                               B.
+ IDR-1002
- IDR peptide
+ IDR-1
Figure 1 Evaluation of MMP-3 production in OA and RA FLS. Human fibroblast-like synoviocytes (FLS) isolated from either (a), osteoarthritis
(OA), or (b), rheumatoid arthritis (RA) synovial tissues were stimulated with pro-inflammatory cytokine IL-1b (10 ng/ml) in the presence and
absence of IDR peptides. Tissue-culture supernatants were monitored for MMP-3 production by ELISA after 24-hour stimulation. Results shown
are an average of at least three independent biologic experiments performed with cells isolated from synovial tissues obtained from
independent donors ± standard error (*P < 0.05). IDR, innate defence regulator; IL, interleukin; MMP-3, matrix metalloproteinase-3.
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Figure 2 Evaluation of MMP-3 and IL-1RA production, and transcriptional response of IL-1RA and SIGIRR. Human fibroblast-like
synoviocytes (FLS) were stimulated with pro-inflammatory cytokines either IL-1b (10 ng/ml) or a combination of IL-1b and TNF-a (10 ng/ml
each), in the presence and absence of IDR peptides. The peptides were added at the time of cytokine stimulation. Tissue-culture supernatants
were monitored for (a), MMP-3 production after 24-hour stimulation, or (b), IL-1RA after 48 hours, with ELISA. Transcriptional responses for (c), IL-
1RA, and (d), SIGIRR, were evaluated with quantitative real-time PCR in human FLS cells stimulated with IL-1b (10 ng/ml) in the presence and
absence of IDR-1002 after 2 hours. Results shown are an average of at least three independent biologic experiments performed with cells
isolated from synovial tissues obtained from independent donors ± standard error (*P < 0.05). IDR, innate defence regulator; IL, interleukin; MMP-
3, matrix metalloproteinase-3.
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Page 7 of 14FLS. To monitor JNK activation, human OA FLS were
treated with IL-1b i nt h ep r e s e n c ea n da b s e n c eo fI D R -
1002 for 15 minutes, followed by IP by using a JNK-spe-
cific antibody. The IP eluates were treated with c-Jun
substrate in the presence of ATP. Phosphorylation of
the c-Jun substrate was evaluated with an anti-phospho-
c - J u n( S e r 7 3 ) - s p e c i f i ca n t i b o d ya sam e a s u r eo fJ N K
activity. We reproducibly demonstrated that IL-1b-
induced JNK activation was abrogated in the presence
of IDR-1002 in human FLS (Figure 4a).
Another member of the MAPK family, p38 MAPK,
plays a critical role in inflammatory diseases, including
in RA [41,42]. Also, p38 MAPK has been demonstrated
to be involved in the immunomodulatory mechanism of
both IDR peptides, IDR-1 and IDR-1002 [15,16]. There-
fore, we evaluated the impact of both these peptides
(that is, IDR-1002 and IDR-1) on IL-1b-induced p38
MAPK activation in human FLS. IL-1b activates p38
MAPK in FLS after 15 minutes of stimulation [28].
Human OA FLS were stimulated with IL-1b in the pre-
sence and absence of the IDR peptides for 15 minutes.
p38 MAPK activity was evaluated by using IP with p38
MAPK (Thr180/Tyr182) monoclonal antibody. The IP
eluates were treated with p38 MAPK substrate ATF-2 in
the presence of ATP. Phosphorylation of the substrate
was monitored in immunoblots, probing with a phos-
pho-ATF-2 (Thr76)-specific antibody as a measure of
p38 MAPK activity. We conclusively demonstrated that
IDR-1002 abrogated IL-1b-induced p38 MAPK activity
in human FLS, whereas peptide IDR-1 had a limited
effect (Figure 4b).
IDR-1002 inhibited IL-1b-induced activation of NF-B
The network-based interrogation of the proteomics data
showed that members of the NF-Bp a t h w a yw e r e
altered by the peptide IDR-1002. Therefore, to confirm
the proteomics data, we evaluated IL-1b-induced activa-
tion of NF-B in the presence and absence of IDR-1002
in synovial fibroblasts. To monitor NF-B direct activa-
tion, a rabbit synovial fibroblast cell line (HIG82) was
transiently transfected with pNFB-MetLuc2-Reporter
Vector (Clontech). The cells were stimulated with IL-1b
(10 ng/ml each), in the presence and absence of either
IDR-1002 or IDR-1. The activation of NF-B was moni-
tored after 6 hours of stimulation by using the Ready-
To-Glow Secreted NF-B Luciferase Reporter Assay
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Figure 3 Monitoring IL-1b-induced MMP-3 and chemokine production on pretreatment with IDR-1002. Human fibroblast-like
synoviocytes (FLS) were pretreated with IDR-1002 for 45 minutes before stimulation with IL-1b (10 ng/ml) for 24 hours. Tissue-culture
supernatants were monitored for (a) MMP-3 production with ELISA, and chemokines, (b) MCP-1, and (c), IL-8 production by using the
BDCytometric Bead Array (CBA) preconfigured human chemokine multiplex system with FACS Caliburflow cytometer (BD Biosciences). Results
shown are an average of three independent biologic experiments performed with cells isolated from synovial tissues of three different donors ±
standard error (*P < 0.05, **P < 0.01). IDR, innate defence regulator; IL, interleukin; MMP-3, matrix metalloproteinase-3.
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Page 8 of 14(Clontech) as per the manufacturer’s instructions. Pep-
tide IDR-1 by itself activated NF-B, which was not
observed by the peptide IDR-1002 (Figure 5a). IL-1b-
induced NF-B activation was significantly (P < 0.05)
n e u t r a l i z e db yI D R - 1 0 0 2( t h el e v e l sw e r eb e l o wt h o s e
observed in control unstimulated cells), but not by the
peptide IDR-1 (Figure 5a).
We also monitored NF-B activation in primary
human OA FLS by evaluating the nuclear translocation
of NF-B subunit p50 after stimulation with IL-1b in
the presence and absence of IDR-peptides. IDR-1002
significantly suppressed IL-1b-induced nuclear translo-
cation of NF-B p50, whereas IDR-1 did not (Figure 5b).
IDR-1002 was internalized in human FLS
Previous studies demonstrated cellular uptake of catio-
nic HDP in monocytic cells, dendritic cells, and epithe-
lial cells, and implicated that inhibition of cellular
uptake/endocytic mobilization interferes with cellular
responses mediated by these peptides [43-45]. In this
study, we wanted to monitor whether the peptide IDR-
1002 was internalized in human FLS. Recent studies
have demonstrated cellular uptake of HDP and IDR
peptides by using biotinylated peptides and have
shown that C-terminal cysteine modification and bioti-
nylation does not alter the immune-modulatory activity
of these peptides [29,43]. Consistent with this, intracel-
lular receptors have been recently demonstrated for
HDP LL-37 and IDR-1 [29,43]. Therefore, we used a
biotinylated IDR-1002 (IDR-1002B) to monitor cellular
uptake in human OA FLS after 15 and 30 minutes of
stimulation. These time points were selected because
we demonstrated that IDR-1002 altered IL-1b-induced
cell signaling after 15 minutes of stimulation (Figure
4). In this study, we showed that IDR-1002B was effec-
tively taken up in human FLS after 15 minutes of sti-
mulation and that the cellular localization was largely
cytosolic (Figure 6).
Discussion
In this study, we examined the use of innate immune-
modulatory IDR peptides in limiting IL-1b-induced
inflammatory responses in synovial fibroblasts. We
demonstrated that a 12-amino-acid IDR peptide, IDR-
1002 [16], controlled IL-1b-induced inflammatory
responses in synovial fibroblasts largely by intervening
with IL-1b-induced NF-B, JNK, and p38 MAPK activa-
tion. A recent study demonstrated the ability of IDR-
1002 to protect against bacterial infections largely by
modulating host immune responses [16]. A distinct
advantage of the class of IDR peptides is the likelihood
that these agents can control inflammation while main-
taining elements of innate immunity required for effi-
cient anti-infective mechanisms [3,14,15,46], which is
speculated to be distinct from current anti-TNF
therapies.
In this study, we showed that IDR-1002 significantly
suppressed IL-1b-induced MMP-3 and MCP-1 protein
production in FLS. MMP-3 (stromelysin 1) is known to
be elevated in both OA and RA, and it promotes the
destruction of matrix components of the joints [21].
MCP-1 is a monocyte chemoattractant highly expressed
in the synovial fluid and tissues of RA patients [47]. Pro-
duction of MCP-1, either by macrophages or by FLS,
results in an autocrine or paracrine stimulation of cells
within the synovial microenvironment, resulting in over-
all extracellular matrix degradation [48]. For example,
MCP-1 increases collagenase activity and induces MMP-
3 release from chondrocytes [48]. Therefore, significant
suppression of IL-1b-induced production of both MMP-
3 and MCP-1 in human FLS demonstrates the therapeu-
tic potential of IDR-1002.
-phospho-c-Jun
(Ser73)
A.
B.
Ctrl
IL-1B +
IDR-1002
IL-1B
Ctrl IL-1B +
IDR-1002
IL-1B
(i)     (ii) (i)     (ii)
IL-1B +
IDR-1
- phospho-ATF-2
(Thr76)
IP
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Figure 4 Evaluation of JNK and p38 MAPK activation. (a)
Human fibroblast-like synoviocytes (FLS) were stimulated with IL-1b
(10 ng/ml) in the presence and absence of IDR-1002 for 15 minutes.
Immunoprecipitation (IP) was performed by using 20 μg of cell
lysates with a JNK-specific antibody. The IP eluates were incubated
with c-Jun substrate and ATP mixture, and the kinase activity
specific to JNK was monitored by monitoring the phosphorylation
of the substrate by using an anti-phospho-c-Jun (Ser73)-specific
antibody. (b) Human FLS were stimulated with IL-1b (10 ng/ml) in
the presence and absence of either IDR-1002 or IDR-1 for 15
minutes. The peptides were added either (i) 45 minutes before or
(ii) at the time of cytokine stimulation. IP was done by using 10 μg
of cell lysates with a p38-specific antibody, and the IP eluates were
incubated with substrate ATF-2 protein and ATP mixture. Kinase
activity specific to p38 MAPK was evaluated in immunoblots
probing with a phospho-ATF-2 (Thr76)-specific antibody. The
immunoblots shown are representative of three independent
experiments performed with cells isolated from synovial tissues of
three different donors. IDR, innate defence regulator; IL, interleukin;
JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein
kinase; MMP-3, matrix metalloproteinase-3.
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Page 9 of 14We showed that even though IDR-1002 significantly
suppressed IL-1b-induced MMP-3 production (Figures 1
and 3a), and chemokine MCP-1 production (Figure 3b),
the peptide did not significantly suppress the expression
of an anti-infective neutrophil chemokine (that is, IL-8
production in human FLS; Figure 3c). In contrast, IDR-
1002 induced gene expression of endogenous inhibitor
of IL-1b (for example, IL-1RA (Figure 2c) and enhanced
IL-1b-induced production of IL-1RA protein (Figure 2b)
in human FLS). It should be noted that recombinant IL-
1RA (anakinra) has been extensively explored as a
potential therapy for RA [33]. This selective and differ-
ential modulation of inflammatory responses by the
IDR-peptide is consistent with previous studies. For
example, both HDP and IDR peptides can modestly
induce classic pro-inflammatory responses, such as cer-
tain chemokine production in macrophages required for
anti-infective immunity [3,15,16]. In contrast, these pep-
tides significantly induce anti-inflammatory mediators
such as IL-10 [3,15,16]. These peptides result in a net
balancing of inflammation. In this study, we showed
such “selective” modulation of cytokine-mediated
inflammatory response by IDR-1002 in synovial fibro-
blasts. Thus, based on previous study [16] and this
study, we can speculate that IDR-1002 can exhibit a tar-
geted immune-modulatory activity on both immune
cells (for example, macrophages [16]), and mesenchymal
cells, such as FLS.
We demonstrated that IDR-1002 modulated IL-1b-
induced responses in synovial fibroblasts primarily by
intervening with the activation of JNK and p38 MAPK
(Figure 4) and NF-B (Figure 5) signaling pathways. In
this study, it was demonstrated that IDR-1002 suppressed
IL-1b-induced proteins that are regulated by the JNK and
NF-B pathways (Additional file 1, Table S2). Consistent
with this, by using immunochemical assays, we showed
that IDR-1002 abrogated both IL-1b-induced JNK and
p38 MAPK activity in human FLS (Figure 4), and signifi-
cantly suppressed the IL-1b-induced activation of NF-B
in synovial fibroblasts (Figure 5). These results are con-
sistent with previous studies that have demonstrated that
both HDP and IDR-peptides can influence MAPK path-
ways and selectively modulate pathogen-induced NF-B
regulation [3,15,16,49]. IL-1b-induced JNK and p38
MAPK are critical in the induction of MMPs and subse-
quent tissue destruction in arthritis [42,50]. Conse-
quently, both JNK and p38 MAPK are defined as a
valuable therapeutic targets for arthritis [51-53]. It should
be noted that HDP (for example, the human cathelicidin
LL-37) by itself can transiently and differentially activate
the NF-B subunits [49]. However, in this study, IDR-
1002 did not induce NF-Ba c t i v i t yb yi t s e l fi ns y n o v i a l
fibroblasts at the time point monitored (Figure 5a).
Taken together, this is consistent with the paradigm of
“selective” immunomodulation of inflammatory
responses by HDP and IDR-peptides (that is, suppression
of excessive activation of NF-B in the presence of exo-
genous infectious/inflammatory stimuli, while maintain-
ing transient NF-B activity), overall resulting in a net
balanced inflammation.
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Figure 5 Monitoring activation of NF-B. (a) Rabbit synovial fibroblast HIG-82 cells were transiently transfected with pNFB-MetLuc2-Reporter
Vector (Clontech). The transfected cells were stimulated with IL-1b (10 ng/ml), in the presence and absence of either IDR-1002 or IDR-1. The
activation of NF-B was monitored after 6 hours of stimulation by using Ready-To-Glow Secreted NF-B Luciferase Reporter Assay (Clontech) as
per the manufacturer’s instructions. Results shown are an average of at least three independent experiments ± standard error (*P < 0.05; NS,
nonsignificant). (b) Nuclear extracts of human fibroblast-like synoviocytes (FLS) stimulated with IL-1b (10 ng/ml) in the presence and absence of
either IDR-1002 or IDR-1 were probed with NF-B p50 antibody or b-actin antibody in immunoblots. IDR-1002 was added either (i) 45 minutes
before, or (ii) at the time of cytokine stimulation. Result shown is a representative blot of three independent experiments performed with FLS
obtained from three different donors. IDR, innate defence regulator; IL, interleukin; NF-B, nuclear factor-kappaB.
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analysis of the proteomics data in this study was the
implication of the involvement of transcription factor
HNF-4a-targets in IDR-1002-mediated anti-inflamma-
tory activity (Additional file 1, Table S2). A publication
in 2009 by Chenomx Inc. describing the analysis of ser-
ologic metabolite profiles in RA, demonstrated the inter-
connectedness between the IL-1b-induced inflammatory
protein networks and the transcription factor HNF-4a-
mediated signaling. The modulation of HNF-4a-target
elements by IDR peptides warrants further investigation
[54].
In this study we also demonstrated cellular uptake and
cytosolic localization of IDR-1002 in human FLS (Figure
6). Cellular uptake and endocytic mobilization of catio-
nic HDP has been shown in monocytic cells and epithe-
lial cells, and it was previously suggested that cellular
uptake may be essential for immune-modulatory activity
for cationic peptides [43,44]. Even though some
intracellular interacting protein partners and putative
cell-surface receptors have been identified for both
human HDP LL-37 and IDR-1 [29,43,55], the mechan-
ism of receptor interaction for IDR peptides is yet to be
completely elucidated. A recent study suggested that
IDR-1002 activity may be mediated by a Gi-coupled
receptor [16]; however, no direct interacting protein
partner or receptor has been defined for IDR-1002.
T a k e nt o g e t h e r ,b a s e do np r e v i o u ss t u d i e sa n dt h i s
study, we can speculate the action of IDR-1002 on FLS
as follows. IDR-1002 may be internalized by FLS either
interacting with putative cell surface receptors or, more
likely, by inserting directly into the cell membrane, as
proposed by previous studies for cationic peptides
[45,56]. A vesicle-mediated uptake pathway, as pre-
viously implicated for HDP [44,45,56], is likely to facili-
tate the internalization of IDR-1002, and subsequent
interaction with putative intracellular interacting protein
partners or receptors, as described for other HDP and
50 ¾ m
Figure 6 Evaluating cellular uptake of IDR-1002. Human fibroblast-like synoviocytes (FLS) were stained fluorescently to demonstrate the
uptake of IDR-1002. The cells were stimulated with 100 μg/ml biotinylated IDR-1002 (IDR-1002B). Cells were either (a), not treated with peptide,
or stimulated with IDR-1002B for (b), 0 minutes, (c), 15 minutes, or (d), 30 minutes. Cells were washed, fixed, and stained for actin by using
Alexa Fluor 546 phalloidin (red) and stained with Streptavidin Alexa Fluor 488 conjugate to detect IDR-1002B (green). Hoescht 33258 was used
to counterstain the nucleus (blue). The scale bar in (d) represents a length of 50 μm. IDR, innate defence regulator.
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Page 11 of 14IDR peptides [29,43]. Identification of intracellular
receptors for IDR-1002 in mesenchymal cells such as
human FLS warrants further investigation and is beyond
the scope of this article. Interaction of the peptide with
putative intracellular protein partners may be facilitating
alteration of innate immune signaling pathways, overall
resulting in the modulation of inflammatory responses
by IDR-1002 in synovial fibroblasts. Results from this
study provide evidence that supports further research
into the development of IDR-peptides as potential thera-
peutics in immune-mediated chronic inflammatory dis-
eases such as RA.
Conclusions
This study demonstrates that an IDR peptide, based on
naturally occurring innate immune effector HDP, can
selectively modulate IL-1b-induced responses in synovial
fibroblasts. This study showed that IDR-1002 peptide
suppressed IL-1b-induced inflammatory responses by
altering the IL-1b-induced proteome, suppressed IL-1b-
mediated activation of NF-B, MAPK p38, and JNK,
suppressed IL-1b-induced MMP-3 and MCP-1 produc-
tion, but did not neutralize the production of all chemo-
kines that are required for resolution of infections. In
contrast, the peptide enhanced the expression of anti-
inflammatory endogenous inhibitors of IL-1b (for exam-
ple, IL-1RA). Overall, this study showed that an IDR-
peptide can selectively modulate immune-mediated
“sterile” inflammation in mesenchymal cells such as
FLS. This study provides a new potential application of
innate immune IDR-peptides as selective immune-mod-
ulatory agents that are likely to control inflammation
without hampering anti-infective immunity. We propose
that IDR-peptides represent valuable candidates that
should be explored further as potential therapeutics for
inflammatory arthritis and other diseases characterized
by chronic inflammation.
Additional material
Additional file 1: Supplementary Table 1. IL-1b-induced proteins
suppressed in the presence of IDR peptide, IDR-1002. Human
fibroblast-like synoviocytes (FLS) were stimulated with IL-1b (10 ng/ml) in
the presence and absence of IDR-1002 for 24 hours. The peptide was
added 45 minutes before cytokine stimulation. The cell lysates were
processed for iTRAQ labelling by using three different isobaric tags. Three
independent LC-MS/MS runs were performed on iTRAQ-labelled samples
from three independent donors. Protein candidates were selected only if
they were detected in at least two of the three independent biologic
experiments. Eleven proteins induced by IL-1b were found to be
suppressed by IDR-1002 between 20% and 60%. Supplementary Table
2. Computational network-based analysis by using InnateDB
biomolecular network database. IL-1b-induced protein candidates that
were found to be suppressed between 20% and 60% by IDR-1002 (11
proteins) were submitted to InnateDB biomolecular interaction database
[57]. This database was used to identify direct interactions between the
selected 11 protein candidates and any known immunity-related
proteins. The identified interactions are summarized, and the members of
NF-B and JNK pathways, and association of HNF-transcription factor, are
indicated in bold in this table.
Abbreviations
FLS: fibroblast-like synoviocytes; HDP: host defense peptide; IDR: innate
defence regulator; JNK: c-Jun N-terminal kinases; MAPK: mitogen-activated
protein kinase; MCP-1: monocyte chemotactic protein-1; MMP-3: matrix
metalloproteinase-3; NF-κB: nuclear factor kappa-B; OA: osteoarthritis; RA:
rheumatoid arthritis.
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